Recent

% | $
Quotes you view appear here for quick access.

Cempra Inc Message Board

billygbillyg 167 posts  |  Last Activity: Jan 8, 2016 2:49 AM Member since: Jul 9, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    My Thoughts on CEMP

    by golongin2008 Jan 7, 2016 5:38 PM
    billygbillyg billygbillyg Jan 8, 2016 2:49 AM Flag

    You nailed it. I had two stocks do secondary offerings with in a day of each other, PSDV and CEMP. PSDV actually went up the day after they announced their secondary as they priced it at $4 which was only 19 cents below the closing price the day they announced the secondary after the market close. CEMP was at 32 only a few days ago and they do a secondary at 24 !!!

  • Reply to

    Hey......Where Is Blowboy And Nonsense?

    by mickmack50 Dec 22, 2015 9:55 AM
    billygbillyg billygbillyg Dec 22, 2015 12:45 PM Flag

    Mick, I still got my PSDV. It looks like patience is finally starting to pay off. How did the increase in intraocular pressure for this trial compare to that of Iluvien in it's phase III trial?

  • Reply to

    Amiket

    by tomstock64 Sep 16, 2015 5:36 PM
    billygbillyg billygbillyg Oct 2, 2015 4:25 PM Flag

    Tom, I also am wondering when we are going to hear something about the partnering of Amiket. I have been adding more shares as the price has been dropping and now have way more shares now then I should have. I've seen a post here saying partnering Amiket could be worth $20M to $60M to IMNP. With a current market cap of around $30M, getting just $20M could be huge for the stock. I'm wondering why a company would pay that much when they whole company is worth only $30M. But I agree with you they need to get a deal done soon as the stock is getting crushed with all of the uncertainty around Amiket. Maybe the company has to be more realistic now on how much the partnering of Amiket is worth under current market conditions and needs to get a deal done now by taking less money up front for a larger percentage of the profits. With the recent money they have raised this seems doable. I'm hoping they get this done before the phase 2 results are released because a negative phase 2 result with no Amiket deal could really destroy the stock.

  • Reply to

    So.....Is It Another Buying Opportunity?

    by mickmack50 Aug 24, 2015 10:27 AM
    billygbillyg billygbillyg Sep 10, 2015 6:12 PM Flag

    Mick, glad to see you are still active on this board. I haven't been checking this board much lately as I was trying to take a buy it and forget it approach to PSDV. But I wanted to check in after the latest earnings report. I did take an opportunity to add some more at $3.73 today as I still think it is a great long term investment for those with some patience. You are right about this company still being under the radar though. I was very annoyed with my stock broker Scottrade last month when I tried to buy some PSDV on line and was told I could no longer trade PSDV online but I would have to call my broker to place a trade. This went on for several weeks and I called to complain about it saying there had been no recent news or developments that would cause them to stop trading PSDV online and I had been trading it for several years online prior to this. They gave me a story about it was probably suspended from online trading because of low volume. Yet I have other stocks that trade at lower volumes than PSDV and they still trade online at Scottrade. Apparently all they care about is volume and not quality as I have another stock ADMD which I have been expecting to go bankrupt for several years now but it keeps hanging on some how and you can still trade it online. It has a market cap of $3M and the current price is around .0016 and it traded 39M shares today. I guess they care more about all of the commissions they are making then protecting the investor. I don't know if my complaining helped or not but they did put PSDV trading back online for trading a couple of weeks later.

  • billygbillyg by billygbillyg Mar 5, 2015 2:23 AM Flag

    3/4/2015 two more hospitals, one in L.A. and another in Hartford
    Connecticut, reported patients had become infected with CRE. 4 were infected and
    67 at risk at Cedars-Sinai Medical Center in L.A. and another 5 infected and
    280 at risk in Hartford Connecticut.

    3/4/2015 A duodenoscope was also responsible for CRE infections at Wisconsin hospitals in 2013 but was
    not reported. Jennifer Miller, a communications specialist with
    Wisconsin's state health department, said the state did not notify the
    FDA or the Centers for Disease Control and Prevention about the
    outbreak or that the scopes appeared to be the source of those
    infections because it isn't required to do so.

    3/4/2015 Another story says that the duodenoscopes that caused the CRE
    infections at the UCLA Medical Center and were sold by Olympus were
    modified and sold without notifying the FDA 90 days prior as required
    by law.
    Rep. Ted Lieu, a newly elected Democratic congressman who represents
    part of Los Angeles, said Wednesday he's considering legislation that
    would require states to report superbug outbreaks and medical device
    failures to certain federal agencies

    Sentiment: Buy

  • BMY's Opdivio today gained quick expanded approval to treat patients with squamous non-small cell lung cancer no longer responsive to chemotherapy only one week after being accepted. This should be good news for AGEN as it is also developing checkpoint inhibitors.

    Sentiment: Buy

  • Reply to

    Should or Could Novartis Buy Array?

    by billygbillyg Feb 18, 2015 6:36 PM
    billygbillyg billygbillyg Feb 21, 2015 6:21 PM Flag

    I tend to agree with you it looks like 2016 is setting up to be a big year for ARRY if everything falls into place. See my reply to donsjoe3 above. I've been reluctant to add more ARRY since I first boughtt in at 4.48 but after reading through the last earnings report I think it still has room to run and 2016 could be a break out year for the stock so I'm planning on adding some more on Monday as my present position is quite small only 300 shares.

    Sentiment: Buy

  • Reply to

    Should or Could Novartis Buy Array?

    by billygbillyg Feb 18, 2015 6:36 PM
    billygbillyg billygbillyg Feb 21, 2015 6:15 PM Flag

    Unfortunately I only bought small positions in ARRY and CRIS. I thought I'd only take small positions in these two stocks because they seemed the riskiest at the time. As it turns out they have been my best performers with ARRY a double and CRIS a triple. I'm thinking of adding more ARRY on Monday. I've been reading over the last earnings report and if AstraZeneca gets approval this year for selumetinib it looks like 2016 could be a huge year for ARRY with revenue to start coming in from AstraZeneca and the possibility of ARRY fillings for two drug approvals. Also top line results from the pivotal trial in KRAS lung cancer are expected in mid-2016. So I'm thinking now might be a good time to add more as 2016 could be a break out year for ARRY

    Sentiment: Buy

  • Reply to

    So, Are We Waiting For Partners?

    by mickmack50 Feb 11, 2015 8:29 PM
    billygbillyg billygbillyg Feb 19, 2015 5:26 PM Flag

    Mick, Glad to see you are still keeping busy on the PSDV message board and that we are finally getting some upward price movement in PSDV stock. I've still got my core position but I've been spending a lot of time on the AKAO board as that is another stock that I like and PSDV and AKAO are now my two largest positions. It's been a good day for AKAO as it was up a lot due to the reported CRE outbreak at the UCLA Medical Center yesterday after the stock market was closed, Anyway I'm expecting big things in the future from both AKAO and PSDV and plan to keep core positions in both stocks. I would like to add more PSDV if it drops close to $4 and AKAO if it drops close to $11.
    Good luck

    Sentiment: Hold

  • Reply to

    Can you spell

    by yabadabadoski Feb 17, 2015 5:20 PM
    billygbillyg billygbillyg Feb 19, 2015 12:59 PM Flag

    I agree I did buy a very small position in CFRX just to keep long term. I've been keeping a core position in AKAO and also added some more at 11.11 to trade and I was able to sell those shares today at 11.72

  • Reply to

    Can you spell

    by yabadabadoski Feb 17, 2015 5:20 PM
    billygbillyg billygbillyg Feb 19, 2015 12:30 PM Flag

    You can email me at my gmail account wag12wag12

    Sentiment: Strong Buy

  • Reply to

    Billygbillyg

    by siamesekitty711 Feb 19, 2015 11:21 AM
    billygbillyg billygbillyg Feb 19, 2015 12:23 PM Flag

    You can send to my gmail account wag12wag12

    Sentiment: Strong Buy

  • billygbillyg by billygbillyg Feb 19, 2015 12:13 PM Flag

    I tried to post this message yesterday but Yahoo kept deleting it so I'll give it one more try today. I'll have to give credit to Kitty for alerting me to this story yesterday. I found that the website HEAVY had a very good story about CRE. Google: HEAVY CRE UCLA medical Center and look for the link from HEAVY.

    Sentiment: Strong Buy

  • Reply to

    Billygbillyg

    by siamesekitty711 Feb 19, 2015 11:21 AM
    billygbillyg billygbillyg Feb 19, 2015 12:03 PM Flag

    You can email me at wag12wag12@gmail.com
    Thanks for the heads up about the CRE outbreak at the UCLA Medical Center yesterday.
    I tried to post a message here about it buy Yahoo kept deleting it so I finally gave up.

    Sentiment: Strong Buy

  • billygbillyg by billygbillyg Feb 19, 2015 3:45 AM Flag

    I'll give credit to Kitty for alerting me to this story first. I found the best information on the story at the HEAVY website. Just Google: Heavy CRE UCLA Medical Center for the link. CRE kills two, infects seven, and over 100 exposed at the UCLA Medical Center. The UCLA outbreak was caused by a specialized duodenoscope inserted down a patient’s throat.

    Sentiment: Strong Buy

  • billygbillyg by billygbillyg Feb 19, 2015 3:43 AM Flag

    I'll give credit to Kitty for alerting me to this story first. I found the best information on the story at the HEAVY website. Just Google: Heavy CRE UCLA Medical Center for the link. CRE kills two, infects seven, and over 100 exposed at the UCLA Medical Center. The UCLA outbreak was caused by a specialized duodenoscope inserted down a patient’s throat.

    Sentiment: Strong Buy

  • I'll give credit to Kitty for alerting me to this story first. I found the best coverage of the story at the website HEAVY. Just Google: heavy com CRE UCLA for the link.
    CRE infects seven, kills two, and over 100 patients may have been exposed at the UCLA Medical Center.
    The UCLA outbreak was caused by a specialized duodenoscope inserted down a patient’s throat.

    Sentiment: Strong Buy

  • I'll give credit to Kitty for alerting me to this story first. I found that heavy.com had the most complete information on this story so for more information Google heavy.com UCLA CRE
    CRE has infected seven patients two of which have died. More than 100 patients may have been exposed. The UCLA outbreak was caused by a specialized duodenoscope inserted down a patient’s throat

    Sentiment: Strong Buy

  • Reply to

    Can you spell

    by yabadabadoski Feb 17, 2015 5:20 PM
    billygbillyg billygbillyg Feb 19, 2015 1:16 AM Flag

    Kitty have you looked at CFRX it is also in early stages but article at SA suggests it might interesting for a small long term investment. Looking forward to finding out what company you thought could be an easy double. I also had bought CEMP at $9 but sold it too early at $23. I ended up keeping TRSX until the buyout by CBST but didn't make much because of the low buyout price. So looking for a similar stock I ended up here with AKAO.

  • I'm a new owner of ARRY; I just bought last Jan 6th. I've been reading through the last earnings call transcript and it sounds to me like ARRY is coming out way ahead with their deal with Novartis. If I have this right Novartis is going to return two drugs and $85M and continue to pay part of the development costs. This doesn't sound like a good deal for Novartis. I understand they are required to do this because of a deal they made with GSK. My question is couldn't Novartis just buy ARRY instead and wouldn't this make more sense then returning these drugs or is there something in their deal with GSK that would prevent them buying ARRY?

    Sentiment: Strong Buy

CEMP
24.20+0.32(+1.34%)12:57 PMEDT